Month: November 2022

Optimization on the conversion of bamboo shoot shell to levulinic acid with environmentally benign acidic ionic liquid and response surface analysis was written by Zhou, Cunshan;Yu, Xiaojie;Ma, Haile;He, Ronghai;Vittayapadung, Saritporn. And the article was included in Chinese Journal of Chemical Engineering in 2013.Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

Levulinic acid (LA) has been identified as a promising green, biomass derived platform chem. Response surface anal. (RSA) with a four-factor-five-level central composite design (CCD) was applied to optimize the hydrolysis conditions for the conversion of bamboo (Phyllostachys Praecox f. preveynalis) shoot shell (BSS) to LA catalyzed with ionic liquid[C₄min]HSO₄. The effects of four main reaction parameters including temperature, time, C_[C4min]HSO4 (initial [C₄mim]HSO₄ concentration) and X_BSS (initial BSS intake) on the hydrolysis reaction for yield of LA were analyzed. A quadratic equation model for yield of LA was established and fitted to the data with an R² of 0.9868, and effects of main factors and their corresponding relationships were obtained with RSA. Model validation and results of CCD showed good correspondence between actual and predicted values. The anal. of variance (ANOVA) of the results indicated that the yield of LA in the range studied was significantly (P < 0.05) affected by the four factors. The optimized reaction conditions were as follows: temperature of 145°C, time of 103.8 min, C_[C4min]HSO4 of 0.9 mol · L^-1 and X_BSS of 2.04% (by mass), resp. A high yield [(71 ± 0.41)% (by mol), triplicate experiment] was obtained at the optimum conditions of temperature of 145°C, time of 104 min, C_[C4min]HSO4 of 0.9 mol · L^-1 and X_BSS of 2% (by mass), which obtained from the real experiments, concurred with the model prediction [73.8% (by mol) based on available C₆ sugars in BSS or 17.9% (by mass) based on the mass of BSS], indicating that the model was adequate for the hydrolysis process. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Flammability, thermal stability, and phase change characteristics of several trialkylimidazolium salts was written by Fox, Douglas M.;Awad, Walid H.;Gilman, Jeffrey W.;Maupin, Paul H.;De Long, Hugh C.;Trulove, Paul C.. And the article was included in Green Chemistry in 2003.Safety of 1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) The following contents are mentioned in the article:

Room temperature ionic liquids (RTILs) have emerged as tunable and potentially “greener” solvents for a multitude of applications. To investigate the solvent properties and potential use as a thermal fluid, a study was initiated to determine the effects of anion type, C-2 hydrogen substitution, and alkyl chain length on the flammability, thermal stability, and phase change characteristics of 1,2,3-trialkylimidazolium room temperature ionic liquids A Setaflash flash point apparatus was used to determine the flammabilities of the RTILs. No flash points were detected for any of the imidazolium based RTILs below 200°, the maximum temperature of the instrument. The thermal stabilities of the RTILs were measured using the technique of thermogravimetric anal. The 1,2,3-trialkylimidazolium compounds exhibit slightly higher thermal stabilities than the comparable 1,3-dialkylimidazolium compounds; RTILs with nucleophilic anions decompose about 150° lower than RTILs with bulky fluoride containing anions; the alkyl chain length does not have a large effect on the thermal stability of the RTILs; and the pyrolysis decomposition exhibits higher thermal stabilities via a different mechanism than the oxidative decomposition In addition, it was found that although the calculated onset temperatures were above 350°, significant decomposition does occur 100° or more below these temperatures The phase change behaviors of several imidazolium based RTILs were characterized by differential scanning calorimetry. The m.ps. of the RTILs increased with increasing alkyl chain length. Most of the salts studied exhibited significant undercooling, which decreased as the length of the alkyl chain was increased. The hexafluorophosphate and bromide RTILs exhibited polymorphic and liquid crystalline behaviors as the alkyl chain length was increased above C10. The clearing point temperatures increased more rapidly with alkyl chain length than the m.p. temperatures This study involved multiple reactions and reactants, such as 1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) (cas: 157310-73-1Safety of 1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V)).

1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) (cas: 157310-73-1) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Safety of 1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V)

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015 was written by Ko, Bor-Sheng;Chen, Li-Ju;Huang, Huai-Hsuan;Chen, Ho-Min;Hsiao, Fei-Yuan. And the article was included in International Journal of Clinical Practice in 2021.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is one of the most frequent types of leukemia/lymphoma in adults in Western countries. However, there are few studies regarding its epidemiol. and treatment patterns in Asian countries. To investigate CLL/SLL in Asian populations, we identified CLL/SLL patients diagnosed during 2006 to 2015 from the Taiwan Cancer Registry Database and estimated the incidence. Further, patients diagnosed during 2008 to 2015 were included for the anal. of treatment patterns and survivals. Treatments for CLL/SLL were retrieved from the Taiwan’s National Health Insurance Research Database and survival data from the National Death Registry. In total, 1497 patients who were older than 20 years and had newly diagnosed CLL/SLL during 2006-2015 were identified. The age-standardized incidence rates of CLL/SLL (0.36 per 100 000 persons in 2006, and 0.54 in 2015) increased during the 10-yr period. The sex ratio was ranged from 1.21 to 2.63 with male predominant during 2006 and 2015. For the anal. of treatment patterns (n = 1236), 72.8% patients received chemotherapies. The median duration between the diagnosis and start of treatments was 27 days, and monotherapy of chlorambucil, bendamustine or cyclophosphamide was the most common regimen in initial treatments. The median follow-up duration for the patients receiving therapies was 29.6 mo, and 45.0% patients experienced relapse or refractory. In patients with relapse/refractory CLL/SLL, 34.1% received rituximab-containing chemotherapies. Three hundred and ninety-nine (32.3%) patients received intensive treatments, and 175 (43.9%) of them received rituximab-containing chemotherapies. The 5-yr overall survival (OS) rate was 61%, and age was an important prognostic factor for CLL/SLL patients. This study is the first population-based study in Asia and provides comprehensive evidence of epidemiol., treatment patterns and survivals of CLL/SLL in an Asian population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial was written by Casulo, Carla;Santoro, Armando;Cartron, Guillaume;Ando, Kiyoshi;Munoz, Javier;Le Gouill, Steven;Izutsu, Koji;Rule, Simon;Lugtenburg, Pieternella;Ruan, Jia;Arcaini, Luca;Casadebaig, Marie-Laure;Fox, Brian;Kilavuz, Nurgul;Rettby, Nils;Dell′Aringa, Justine;Taningco, Lilia;Delarue, Richard;Czuczman, Myron;Witzig, Thomas. And the article was included in Cancer Reports (New York, NY, United States).Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematol. malignancies. Phase 1/2 FUSION NHL 001 was designed to determine the safety and efficacy of durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, combined with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL). The primary endpoints were to determine the recommended phase 2 dose of the drugs used in combination with durvalumab (durvalumab was administered at the previously recommended dose of 1500 mg every 4 wk) and to assess safety and tolerability. Patients were enrolled into one of four arms: durvalumab monotherapy (Arm D) or durvalumab in combination with lenalidomide ± rituximab (Arm A), ibrutinib (Arm B), or rituximab ± bendamustine (Arm C). A total of 106 patients with relapsed/refractory lymphoma were enrolled. All but two patients experienced at least one treatment-emergent adverse event (TEAE); those not experiencing a TEAE were in Arm C (diffuse large B-cell lymphoma [DLBCL]) and Arm D (DLBCL during the durvalumab monotherapy treatment period). No new safety signals were identified, and TEAEs were consistent with the resp. safety profiles for each study treatment. Across the study, patients with follicular lymphoma (FL; n = 23) had an overall response rate (ORR) of 59%; ORR among DLBCL patients (n = 37) was 18%. Exploratory biomarker anal. showed that response to durvalumab monotherapy or combination therapy was associated with higher interferon-γ signature scores in patients with FL (p = .02). Durvalumab as monotherapy or in combination is tolerable but requires close monitoring. The high rate of TEAEs during this study may reflect on the difficulty in combining durvalumab with full doses of other agents. Durvalumab alone or in combination appeared to add limited benefit to therapy. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

The structural diversity and photoluminescent properties of cadmium thiophenedicarboxylate coordination polymers was written by Xue, Li-Ping;Chang, Xin-Hong;Li, Shi-Hui;Ma, Lu-Fang;Wang, Li-Ya. And the article was included in Dalton Transactions in 2014.Formula: C11H9N5 The following contents are mentioned in the article:

Two series of Cd(II) coordination polymers (CPs), {[Cd(bimm)₂(H₂O)₂][(3,4-tdc)₂][H₂O]₂}_n (1a), [Cd(3,4-tdc)(bimb)]_n (2a), [Cd(3,4-tdc)(bimpy)(H₂O)]_n (3a) and [Cd(2,3-Htdc)₂(bimm)₂]_n (1b), {[Cd(2,3-tdc)(bimb)](H₂O)}_n (2b), [Cd(2,3-tdc)(bimpy)(H₂O)]_n (3b) where H₂tdc = thiophenedicarboxylic acid, bimm = 1,2-bis(imidazol-1′-yl)methane, bimb = 1,2-bis(imidazol-1′-yl)butane and bimpy = 3,5-bis(imidazol-1′-yl)pyridine, have been synthesized by using Cd(II) acetate with H₂tdc and N-donor ligands under hydrothermal conditions. Two related isomeric thiophenedicarboxylic acids were chosen to examine the positional isomeric effect on the construction of these CPs with distinct dimensionality and connectivity. The structure of 1a is a one-dimensional (1D) cationic double chain further forming a two-dimensional (2D) supramol. network via hydrogen-bonding interactions, while 1b exhibits a neutral double chain structure. A three-dimensional (3D) 4-connected cds network for 2a as well as a 1D neutral double chain structure for 2b were obtained in the presence of bimb. When the rigid tripodal bimpy was introduced, isomorphous 3a and 3b with 3D (3,5)-connected (6²·8) (6⁷·8³) nets were constructed. The structural diversity of 1a–2b mainly stems from the positional isomeric effect of thiophenedicarboxylate, while 3a and 3b are well regulated by rigid bimpy. Moreover, the thermal stability and photoluminescence of 1a–3b are investigated. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Formula: C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Formula: C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73 was written by Kumar, Meera;Lowery, Robert;Kumar, Vaishnav. And the article was included in SLAS Discovery in 2020.Category: imidazoles-derivatives The following contents are mentioned in the article:

Production of adenosine in the extracellular tumor microenvironment elicits strong immunosuppression and is associated with tumor progression. Thus, targeting adenosine-generating ectonucleotidases is a potential strategy to stimulate and prolong antitumor immunity. Because the reaction products of ectonucleotidases differ by a single phosphate group, selective detection in an assay format that is compatible with high-throughput screening (HTS) has been elusive. We report the development of biochem. assays capable of measuring the activity of ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1; also known as CD39) and ecto-5′-nucleotidase (CD73). Both assays leverage the Transcreener HTS Assay platform, which facilitates selective immunodetection of nucleotides with homogenous fluorescent readouts, fluorescence polarization or time-resolved fluorescence energy transfer. The Transcreener AMP2 Assay was used to measure CD39 activity, allowing detection of adenosine monophosphate (AMP) production (Z> 0.6) with subnanomolar amounts of CD39, allowing IC50 determination for tool compounds, consistent with previously reported values. To detect the production of adenosine by CD73, the Transcreener ADP2 Assay was coupled with adenosine kinase (AK); conversion of adenosine to AMP and ADP (ADP) by AK allows detection with ADP2 antibody. The Transcreener AMP2 Assay was used to screen a 1280 Library of Pharmacol. Active Compounds (LOPAC) library and a 1600-compound subset of a ChemBridge diversity library for CD39 inhibitors, allowing the identification of nine and eight candidate compounds from each library, resp. The Transcreener ADP2 Assay was used to screen 1600 compounds from the ChemBridge diversity library for CD73 inhibitors and identified 14 potential candidates. HTS-compatible assays for ectonucleotidase activity may allow identification of purinergic signaling pathway inhibitors important for tumor-specific immune responses during tumor pathogenesis. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Category: imidazoles-derivatives).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Simultaneous quantitative analysis of six proton- pump inhibitors with a single marker and evaluation of stability of investigated drugs in polypropylene syringes for continuous infusion use was written by Chen, Fuchao;He, Xudong;Fang, Baoxia;Wang, Sicen. And the article was included in Drug Design, Development and Therapy in 2020.Application of 117976-90-6 The following contents are mentioned in the article:

Objective: We developed and validated a simple, convenient and reproducible method for simultaneous estimation of six proton-pump inhibitors (PPIs), omeprazole (OPZ), esomeprazole (EOPZ), lansoprazole (LPZ), pantoprazole (PPZ), rabeprazole (RPZ) and ilaprazole (IPZ) in pharmaceutical dosage forms by a single marker. Meanwhile, the stability of the cited PPIs in 0.9% sodium chloride injection stored in polypropylene syringes up to 48 h for continuous infusion use was investigated. Materials and Methods: The chromatog. separation was achieved on an InterSustain C18 column (150 x 4.6 mm, 5 μm). The isocratic mobile phase made up of 0.05 M potassium dihydrogen phosphate buffer (pH 4.0): acetonitrile (65:35, volume/volume) was pumped through the column at a temperature maintained at 30°C and a flow rate of 1.0 mL/min. The relative retention time, UV spectral similarity and relative correction factors between OPZ and the other five PPIs were calculated and investigated using the quant. anal. of multi-components with a single marker (QAMS) method. The stability study examined phys. parameters, pH values and drug concentrations of the PPIs mixtures Results: Under these conditions, all cited PPIs were separated simultaneously at a retention time of 6.0, 7.3, 7.3, 9.9, 12.5 and 13.9 min for RPZ, OPZ, EOPZ, IPZ, PPZ and LPZ, resp., with a total run time less than 20.0 min. Comparative anal. results indicated that there were no significant differences observed between the QAMS method and the external standard method. The percentage of initial concentration of each PPI gradually decreased during the storage time. Conclusion: The proposed method, which is selective, economical and accurate, was applied successfully for determination of the cited PPIs in their resp. pharmaceutical dosage forms. Admixtures of OPZ, EOPZ, PPZ, IPZ in 0.9% sodium chloride injection were stable for 24 h and LPZ, RPZ in 0.9% sodium chloride injection were stable for 8 h in polypropylene syringes. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Application of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System was written by Gaimari, Anna;Fusaroli, Michele;Raschi, Emanuel;Baldin, Elisa;Vignatelli, Luca;Nonino, Francesco;De Ponti, Fabrizio;Mandrioli, Jessica;Poluzzi, Elisabetta. And the article was included in Drug Safety in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

Amyotrophic lateral sclerosis is a fatal progressive disease with a still unclear multi-factorial etiol. This study focused on the potential relationship between drug exposure and the development of amyotrophic lateral sclerosis by performing a detailed anal. of events reported in the FDA Adverse Event Reporting System database. The FDA Adverse Event Reporting System quarterly data (Jan. 2004-June 2020) were downloaded and deduplicated. The reporting odds ratios and their 95% confidence intervals were calculated as a disproportionality measure. The robustness of the disproportion was assessed accounting for major confounders (i.e., using a broader query, restricting to suspect drugs, and excluding reports with amyotrophic lateral sclerosis as an indication). Disproportionality signals were prioritized based on their consistency across analyses (reporting odds ratio stability). We retained 1188 amyotrophic lateral sclerosis cases. Sixty-two drugs showed significant disproportionality for amyotrophic lateral sclerosis onset in at least one anal., and 31 had consistent reporting odds ratio stability, including tumor necrosis factor-alpha inhibitors and statins. Disproportionality signals from ustekinumab, an immunomodulator against interleukins 12-23 used in autoimmune diseases, and the anti-IgE omalizumab were consistent among analyses and unexpected. For each drug emerging as possibly associated with amyotrophic lateral sclerosis onset, biol. plausibility, underlying disease, and reverse causality could be argued. Our findings strengthened the plausibility of a precipitating role of drugs primarily through immunomodulation (e.g., tumor necrosis factor-alpha, ustekinumab, and omalizumab), but also by impacting metabolism and the musculoskeletal integrity (e.g., statins and bisphosphonates). Complement and NF-kB dysregulation could represent interesting topics for planning translational mechanistic studies on amyotrophic lateral sclerosis as an adverse drug effect. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data was written by Chen, Gang;Ning, Li-Juan;Qin, Yan;Zhao, Bin;Mei, Dan;Li, Xue-Mei. And the article was included in Journal of Gastroenterology and Hepatology in 2021.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

Background and Aim : Recent evidence has concerned acute kidney injury (AKI) after the proton pump inhibitor (PPI) application. There are few real-world studies to compare the occurrences, clin. features, and prognosis of AKI related to various PPI regimens. We aimed to evaluate and compare the links between different PPIs and AKI in a large population by investigating the Food and Drug Administration Adverse Event Reporting System (FAERS) until recently. Methods : Disproportionality anal. and Bayesian anal. were used in data mining to screen the suspected AKI after different PPIs based on the FAERS from Jan. 2004 to Dec. 2019. The times to onset, fatality, and hospitalization rates of PPI-associated AKI were also investigated. Results : We identified 19 522 PPI-associated AKIs, which appeared to influence more middle-aged patients than elderly ones (53.04% vs 33.94%). Women were more affected than men (55.42% vs 44.58%). Lansoprazole appeared a stronger AKI association than other PPIs, based on the highest reporting odds ratio (reporting odds ratio = 20.8, 95% confidence interval = 20.16, 21.46), proportional reporting ratio (proportional reporting ratio = 15.55, χ2 = 73 899.68), and empirical Bayes geometric mean (empirical Bayes geometric mean = 15.15, 95% confidence interval = 14.76). The median time to AKI onset was 446 (interquartile range [IQR] 16-2176) days after PPI administration. PPIs showed a significant difference in average time to AKI onset (P < 0.001), with the shortest of 9 (IQR 3-25) days for rabeprazole and the longest of 1221 (IQR 96.5-2620) days for esomeprazole. PPI-associated AKI generally led to a 5.69% fatality rate and an 8.94% hospitalization rate. The highest death rate occurred in rabeprazole (15.35%). Conclusions : Based on the FAERS database, we profiled AKI related to various PPIs with more details in occurrences, clin. characteristics, and prognosis. Concern should be paid for PPIs when applied to patients with a tendency for AKI. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Helicobacter pylori therapy for the prevention of metachronous gastric cancer was written by Choi, Il Ju;Kook, Myeong-Cherl;Kim, Young-Il;Cho, Soo-Jeong;Lee, Jong Yeul;Kim, Chan Gyoo;Park, Boram;Nam, Byung-Ho. And the article was included in New England Journal of Medicine in 2018.Formula: C18H20N3NaO3S The following contents are mentioned in the article:

Background: Patients with early gastric cancers that are limited to gastric mucosa or submucosa usually have an advanced loss of mucosal glandular tissue (glandular atrophy) and are at high risk for subsequent (metachronous) development of new gastric cancer. The long-term effects of treatment to eradicate Helicobacter pylori on histol. improvement and the prevention of metachronous gastric cancer remain unclear. Methods: In this prospective, double-blind, placebo-controlled, randomized trial, we assigned 470 patients who had undergone endoscopic resection of early gastric cancer or high-grade adenoma to receive either H. pylori eradication therapy with antibiotics or placebo. Two primary outcomes were the incidence of metachronous gastric cancer detected on endoscopy performed at the 1-yr follow-up or later and improvement from baseline in the grade of glandular atrophy in the gastric corpus lesser curvature at the 3-yr follow-up. Results: A total of 396 patients were included in the modified intention-to-treat anal. population (194 in the treatment group and 202 in placebo group). During a median follow-up of 5.9 years, metachronous gastric cancer developed in 14 patients (7.2%) in the treatment group and in 27 patients (13.4%) in the placebo group (hazard ratio in the treatment group, 0.50; 95% confidence interval, 0.26 to 0.94; P = 0.03). Among the 327 patients in the subgroup that underwent histol. anal., improvement from baseline in the atrophy grade at the gastric corpus lesser curvature was observed in 48.4% of the patients in the treatment group and in 15.0% of those in the placebo group (P<0.001). There were no serious adverse events; mild adverse events were more common in the treatment group (42.0% vs. 10.2%, P<0.001). Conclusions: Patients with early gastric cancer who received H. pylori treatment had lower rates of metachronous gastric cancer and more improvement from baseline in the grade of gastric corpus atrophy than patients who received placebo. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem